This is a working overview of triple agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Archived from the original on January 11, 2013. "Paye ta plainte" [Pay for your complaint]. Le Groupe F (in French). Archived from the original on February 13, 2019. "Laboratoire de l'égalité" [Equality Lab] (in French). Archived from the original on January 18, 2019. "Paye ton taf" [Pay for your work] (in French). Archived from the original on April 13, 2019. "Délégation aux droits des femmes" [Delegation for Women's Rights]. Assemblée Nationale (in French). Archived from the original on June 24, 2020.
Other measures included shifting the National Council of Traditional Peoples and Communities (CNPCT) from the Ministry of Human Rights and Citizenship to the Ministry of Environment and Climate Change, as well as the establishment of the "National Secretariat for Traditional Peoples and Communities and Sustainable Rural Development" under the same ministry.
PyMOL – introduce a set of common PTM's into protein models AWESOME – Interactive tool to see the role of single nucleotide polymorphisms to PTM's Chimera – Interactive Database to visualize molecules
Sources: en.wikipedia.org
Seeking to mend ties with the agribusiness sector, the government launched the 2023–2024 Crop Plan, providing R$ 364 billion in rural credit at interest rates below those prevailing in the financial market. This represented a 27% increase in funds compared to the 2022–2023 edition under the previous administration. The "Family Farming Harvest Plan" was also launched, which sought to strengthen family farming by extending rural credit to small and medium landowners, with around R$ 77.7 billion in resources being released for this plan in 2023-2024, a 34% increase in funding compared to the 2022–2023 edition. For the 2024–2025 edition, the government released R$ 400 billion in resources for large landowners, and R$ 85,7 billion for small and medium ones. The 2025–2026 edition released another R$ 516 billion in rural credit for large landowners, and R$ 78,2 billion for family farming. For the 2026–2027 edition, it released R$ 525.1 billion in credit for the agribusiness and another R$ 85 billion for small farms.
uridine monophosphate (UMP)), usually to tyrosine propionylation pyroglutamate formation S-glutathionylation S-nitrosylation S-sulfenylation, reversible covalent addition of one oxygen atom to the thiol group of a cysteine residue to form a sulfenic acid S-sulfinylation, normally irreversible covalent addition of two oxygen atoms to the thiol group of a cysteine residue to form a sulfinic acid S-sulfonylation, normally irreversible covalent addition of three oxygen atoms to the thiol group of a cysteine residue, resulting in the formation of a cysteic acid residue sulfation, the addition of a sulfate group to a tyrosine.
From the 1830s Haüy's molecular crystal structure theory started to be combined with the atomic theory of the chemists to produce a view of a crystal as the regular arrangement of atoms or molecules in space. In 1849 Auguste Bravais related the symmetry of the crystal, considered as one of 14 space lattices, to that of its constituting molecules and formalized the reticular interpretation of hemihedry given by Gabriel Delafosse. In 1852 Delafosse attempted to relate the structure of the molecule to the external shape of the crystal. During the 1850s and 1860s a "quiet revolution" took place in structural chemistry according to Alan J. Rocke, a historian of chemistry. The main features of the revolution were the clarification of the concept of atomic weight (Stanislao Cannizzaro), the definition of the idea of valence (then known as atomicity), and new chemical structural ideas, such as the benzene structure of a ring of alternating double and single carbon bonds (August Kekulé). These developments in chemistry were largely independent of the mathematical and geometrical direction of crystallography in the period 1850–1895 which had little concern with the practicalities of atomic and molecular arrangement. In 1869 Emanuele Paternò predicted that the four valences of carbon have identical chemical properties and illustrated three predicted isomers of dibromethane showing the tetrahedral carbon atom for the first time. While Paternò's work was the first publication of tetrahedral-valent carbon it is not clear that he recognized the full consequences of the hypothesis.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.